Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PXL 01

Drug Profile

PXL 01

Alternative Names: PXL-01

Latest Information Update: 22 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaSurgics
  • Developer PharmaSurgics; ProMore Pharma; Technomark Life Sciences
  • Class Glycoproteins; Peptides
  • Mechanism of Action Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Plasminogen activator inhibitor-1 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Post-surgical adhesions

Highest Development Phases

  • Phase III Post-surgical adhesions

Most Recent Events

  • 01 Feb 2019 Promore Pharma plans the pivotal phase III PHSU03 trial for Post surgical adhesions (after tendon repair surgery in the hand) in Europe and India by the first half of 2020
  • 19 Nov 2018 Drug Controller General in India (DCGI) approves Promore Pharma's clinical trial application for the phase III PHSU03 study for Post surgical adhesions in India
  • 24 Oct 2018 Promore Pharma plans the pivotal phase III PHSU03 trial for Post surgical adhesions (after tendon repair surgery in the hand) in Europe and India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top